A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia

Trial Profile

A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2018

At a glance

  • Drugs Lintuzumab Ac-225 (Primary) ; Cytarabine; Furosemide; Spironolactone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Actinium Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2017 According to an Actinium Pharmaceuticals media release, Preliminary results from phase II portion were presented at 59th American Society of Hematology Annual Meeting
    • 11 Dec 2017 Preliminary results from phase II portion are presented in an Actinium Pharmaceuticals media release.
    • 01 Nov 2017 According to an Actinium Pharmaceuticals media release, data from phase II part will be presented at the 59th Annual American Society of Hematology (ASH) Meeting & Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top